Long-term outcomes of patients with moderate-severe pediatric systemic lupus erythematosus treated with combination rituximab and cyclophosphamide therapy: A single center cohort experience and review of literature
Authors' conclusion
Our study supports the use of rituximab and cyclophosphamide use in patients with pSLE and demonstrates its efficacy among a racially diverse cohort over the long-term follow-up period.
Study context
- Population
- Patients with moderate-severe pediatric systemic lupus erythematosus (pSLE) treated with combination rituximab (RTX)/CYC therapy between 2013 and 2023 at a single center6 of 11 (55%) Black
- Participants
- 11 patients
- Outcome
- Steroid exposure, SLEDAI scores and SLICC/ACR DI
Methodological detailssingle-centre, with review of literature
- Single-centre
- With review of literature
Main finding
As reported in the abstract
Sustained low disease activity (SLEDAI <4 and prednisone <8 mg/day)
- All patients achieved sustained low disease activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) <4 and prednisone <8 mg/day)
- No statistically significant change in SLICC/ACR DI over time
Observational data: associations, not effects.
Further findings
Outcomes by race
- Positive clinical outcomes observed in all racial groups
Safety
Hemodialysis required
- Patients requiring hemodialysis: 2 of 11 (18%)
- One requiring a transplant
Other adverse effects
- Anaphylaxis and cytopenias
Original publication
Long-term outcomes of patients with moderate-severe pediatric systemic lupus erythematosus treated with combination rituximab and cyclophosphamide therapy: A single center cohort experience and review of literature. Lupus. Published 8 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →